On June 30, 2026, the Africa Centres for Disease Control and Prevention appealed for $18 million in urgent funding to support clinical trials of experimental Ebola treatments in the Democratic Republic of Congo. The trials, set to begin in Bunia, target the rare Bundibugyo strain, which currently has no licensed vaccine or therapy. While vaccine research is funded, a $18 million shortfall threatens therapeutic trials evaluating drugs like obeldesivir and remdesivir.
Story comments
Loading comments…